DE60011571D1 - Verbindungen mit immunologischem adjuvanseffekt - Google Patents

Verbindungen mit immunologischem adjuvanseffekt

Info

Publication number
DE60011571D1
DE60011571D1 DE60011571T DE60011571T DE60011571D1 DE 60011571 D1 DE60011571 D1 DE 60011571D1 DE 60011571 T DE60011571 T DE 60011571T DE 60011571 T DE60011571 T DE 60011571T DE 60011571 D1 DE60011571 D1 DE 60011571D1
Authority
DE
Germany
Prior art keywords
immunological
adjuvane
connections
effect
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60011571T
Other languages
English (en)
Other versions
DE60011571T2 (de
Inventor
D Hawkins
T Ishizaka
Michael Lewis
Pamela Mcguiness
Anneliese Nault
Jeffrey Rose
P Rossignol
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of DE60011571D1 publication Critical patent/DE60011571D1/de
Publication of DE60011571T2 publication Critical patent/DE60011571T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60011571T 1999-02-01 2000-02-01 Verbindungen mit immunologischem adjuvanseffekt Expired - Lifetime DE60011571T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01
US118131P 1999-02-01
PCT/US2000/002755 WO2000044758A1 (en) 1999-02-01 2000-02-01 Immunological adjuvant compound

Publications (2)

Publication Number Publication Date
DE60011571D1 true DE60011571D1 (de) 2004-07-22
DE60011571T2 DE60011571T2 (de) 2005-08-18

Family

ID=22376670

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60011571T Expired - Lifetime DE60011571T2 (de) 1999-02-01 2000-02-01 Verbindungen mit immunologischem adjuvanseffekt
DE60044570T Expired - Lifetime DE60044570D1 (de) 1999-02-01 2000-02-01 Verbindungen mit immunologischem Adjuvanseffekt

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE60044570T Expired - Lifetime DE60044570D1 (de) 1999-02-01 2000-02-01 Verbindungen mit immunologischem Adjuvanseffekt

Country Status (21)

Country Link
US (1) US6290973B1 (de)
EP (2) EP1147117B1 (de)
JP (1) JP4698027B2 (de)
KR (1) KR100711561B1 (de)
AT (2) ATE471328T1 (de)
AU (2) AU768574B2 (de)
BR (1) BRPI0007936B8 (de)
CA (1) CA2361582C (de)
DE (2) DE60011571T2 (de)
DK (1) DK1147117T3 (de)
ES (2) ES2347428T3 (de)
FI (1) FI120689B (de)
HK (2) HK1043132B (de)
HU (1) HU226869B1 (de)
IL (3) IL144671A0 (de)
MX (1) MXPA01007760A (de)
NO (1) NO329111B1 (de)
NZ (1) NZ513259A (de)
PT (1) PT1147117E (de)
WO (1) WO2000044758A1 (de)
ZA (1) ZA200106487B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
JP4598278B2 (ja) * 1999-04-28 2010-12-15 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Ｐｐａｒ受容体リガンドとしてのジアリール酸誘導体
DE60115051T2 (de) * 2000-07-31 2006-08-24 Eisai Co., Ltd. Immunologische adjuvans verbindungen
MXPA03006561A (es) 2001-01-23 2004-10-15 Aventis Pasteur Vacuna del conjugado proteina-polisacarido meningococico, multivalente.
DE60228941D1 (en) * 2001-03-08 2008-10-30 Univ Pennsylvania Faciale amphiphile polymere als antiinfektiöse mittel
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
JP3900343B2 (ja) * 2002-09-05 2007-04-04 株式会社トリケミカル研究所 （ｒｏ）（ｒ’ｏ）（ｒ’’ｏ）ｍ＝ｏの製造方法
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
US8034378B2 (en) * 2002-12-27 2011-10-11 Novartis Vaccines And Diagnostics, Inc Immunogenic compositions containing phospholipid
AU2004222272B2 (en) * 2003-03-17 2010-12-23 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
EP1697389A4 (de) * 2003-10-24 2008-12-24 Eisai R&D Man Co Ltd Verbindungen und verfahren zur behandlung von mit dem toll-like receptor 2 in zusammenhang stehenden krankheiten und leiden
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
US8222456B2 (en) * 2004-01-23 2012-07-17 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
JP2008531585A (ja) * 2005-02-25 2008-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 表面が両親媒性のポリマーおよびオリゴマー、それらの組成物そして癌治療方法におけるそれらの使用
CA2605749C (en) 2005-04-26 2015-06-30 Eisai Co., Ltd. Compositions and methods for cancer immunotherapy
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN103012169B (zh) * 2005-06-30 2016-04-20 卫材R&D管理有限公司 用于制备免疫佐剂的化合物
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
CN102149675B (zh) * 2007-12-18 2014-08-20 卫材R&D管理有限公司 用于免疫佐剂E6020之合成前体的β-酮酰胺合成的试剂和方法
JP5511660B2 (ja) 2008-06-04 2014-06-04 一般財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
US20150133551A1 (en) 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
EP2972399B1 (de) 2013-03-15 2020-09-02 Beth Israel Deaconess Medical Center, Inc. Lipide zur erhöhung der insulinempfindlichkeit und verfahren zur verwendung davon
JP6659535B2 (ja) 2013-06-28 2020-03-04 オークランド ユニサービシーズ リミティド アミノ酸及びペプチド接合体及び接合方法
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
KR20180128915A (ko) 2016-02-26 2018-12-04 오클랜드 유니서비시즈 리미티드 아미노산 및 펩티드 접합체 및 접합 방법
US11013711B2 (en) 2016-06-10 2021-05-25 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (FAHFAs) for use in the treatment of type 1 diabetes
NL2027383B1 (en) 2020-01-24 2022-04-06 Aim Immunotech Inc Methods, compositions, and vaccines for treating a virus infection
CN113307824B (zh) * 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2583892A (en) * 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
AU1218295A (en) * 1993-12-09 1995-06-27 Heinrich Exner Adjuvant for antigens, process for producing the same and its use
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof

Also Published As

Publication number Publication date
CA2361582A1 (en) 2000-08-03
WO2000044758A1 (en) 2000-08-03
IL144671A0 (en) 2002-05-23
KR20010101912A (ko) 2001-11-15
NZ513259A (en) 2004-05-28
HK1043132A1 (en) 2002-09-06
IL174413A0 (en) 2009-02-11
HUP0105473A3 (en) 2003-11-28
DE60044570D1 (de) 2010-07-29
EP1147117B1 (de) 2004-06-16
DE60011571T2 (de) 2005-08-18
AU768574B2 (en) 2003-12-18
FI120689B (fi) 2010-01-29
DK1147117T3 (da) 2004-10-25
JP4698027B2 (ja) 2011-06-08
EP1439184A1 (de) 2004-07-21
ES2223464T3 (es) 2005-03-01
FI20011593A (fi) 2001-07-31
NO20013749D0 (no) 2001-07-31
PT1147117E (pt) 2004-10-29
ZA200106487B (en) 2002-08-07
US6290973B1 (en) 2001-09-18
AU2004201147B2 (en) 2008-04-03
HU226869B1 (en) 2010-01-28
BR0007936A (pt) 2002-04-09
KR100711561B1 (ko) 2007-04-27
HK1043132B (zh) 2005-04-01
EP1147117A1 (de) 2001-10-24
ATE471328T1 (de) 2010-07-15
JP2002535411A (ja) 2002-10-22
BR0007936B1 (pt) 2015-03-10
ATE269341T1 (de) 2004-07-15
BRPI0007936B8 (pt) 2021-05-25
NO329111B1 (no) 2010-08-30
AU2867500A (en) 2000-08-18
NO20013749L (no) 2001-09-25
HUP0105473A2 (hu) 2002-04-29
AU2004201147A1 (en) 2004-04-22
MXPA01007760A (es) 2003-06-24
HK1070372A1 (en) 2005-06-17
CA2361582C (en) 2010-04-06
IL144671A (en) 2006-07-05
ES2347428T3 (es) 2010-10-29
EP1439184B1 (de) 2010-06-16

Similar Documents

Publication Publication Date Title
DE60011571D1 (de) Verbindungen mit immunologischem adjuvanseffekt
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
MXPA04002490A (es) Interleucina-12 como adyuvante de vacuna veterinaria.
ATE397942T1 (de) Adjuvanszusammensetzungen zur erhöhung der immunantwort bezüglich polynukleotid-basierenden impfstoffen
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
DK1372708T3 (da) Vaccine til transkutan immunisering mod rejsediarre
DE60115051D1 (de) Immunologische adjuvans verbindungen
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
DK1112747T3 (da) Salmonellavaccine, som ikke inducerer antistoffer mod flagellin eller flageller
EA200800917A1 (ru) Адъюванты для вакцин
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
WO1992006113A3 (en) Derivatives of gp160 and vaccines based on gp160 or a derivative thereof, containing an adjuvant
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
WO2006109186A3 (en) Early endosome neutralising compouds as vaccine adjuvants
DK1401492T3 (da) LTB4 som vaccineadjuvans
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: EISAI R&D MANAGEMENT CO., LTD., TOKIO, JP

8328 Change in the person/name/address of the agent

Representative=s name: MEISSNER, BOLTE & PARTNER GBR, 80538 MUENCHEN